12.09.15
Kevin Hambly has been appointed vice president, business development and licensing for Catalent Biologics. Mr. Hambly will be responsible for leading business development activities around Catalent’s SMARTag bioconjugation platform, as well as further developing and commercializing Catalent Biologics’ portfolio of technologies.
Mr. Hambly joins the company from Seattle Genetics, where he spent the past nine years, most recently as director of business development responsible for leading out-licensing activities for the company’s Antibody Drug Conjugate (ADC) technology. He was also responsible for negotiating multiple ADC license agreements and was instrumental in driving strategic collaborations and in-licensing efforts.
“Kevin is a seasoned business development professional who has driven multiple high value deals for one of the leaders in Antibody Drug Conjugation technology,” commented Mike Riley, vice president and general manager of Catalent Biologics. “Kevin will play a key role as we continue to build Catalent Biologics into a leading solutions provider, which will help enable the next generation of biologic therapies.”
Catalent’s SMARTag site-specific protein-modification and linker technologies were developed by Redwood Bioscience (acquired in 2014) to enable the generation of homogenous bioconjugates (including ADCs and other protein conjugates) engineered to enhance potency, safety and stability.
Mr. Hambly joins the company from Seattle Genetics, where he spent the past nine years, most recently as director of business development responsible for leading out-licensing activities for the company’s Antibody Drug Conjugate (ADC) technology. He was also responsible for negotiating multiple ADC license agreements and was instrumental in driving strategic collaborations and in-licensing efforts.
“Kevin is a seasoned business development professional who has driven multiple high value deals for one of the leaders in Antibody Drug Conjugation technology,” commented Mike Riley, vice president and general manager of Catalent Biologics. “Kevin will play a key role as we continue to build Catalent Biologics into a leading solutions provider, which will help enable the next generation of biologic therapies.”
Catalent’s SMARTag site-specific protein-modification and linker technologies were developed by Redwood Bioscience (acquired in 2014) to enable the generation of homogenous bioconjugates (including ADCs and other protein conjugates) engineered to enhance potency, safety and stability.